ABSTRACT
There are various data on negative impact of comorbidities on treatment outcomes in patients with novel coronavirus infection (COVID-19). However, the impact of cardiovascular diseases and especially their therapy on the course of infectious process and unfavorable outcomes in COVID-19patients has not been sufficiently studied. Objective. To assess the impact of concomitant cardiovascular diseases and chronic drug intake for their treatment on in-hospi-tal mortality in ICU patients with COVID-19. Material and methods. A single-center retrospective cohort study of ICU patients with COVID-19 was carried out between March 6, 2020 and June 3, 2020 at the Demikhov Moscow City Clinical Hospital. We analyzed the following data: age, gender, previous comorbidities, Charlson comorbidity index, therapy of chronic cardiovascular diseases, severity of COVID-19, NEWS and SOFA scores. Univariate analysis included assessment of relative risk (RR). Multivariate analysis was carried out using regression model. Results. We analyzed medical records of 403 patients (231 (57.3%) men). Mean age of patients was 62.4±15.3 years. Over-all 30-day mortality rate was 44.9% (n=181). Multivariate analysis showed that coronary artery disease (adj. OR 2.459, 95% CI 1.589—3.806, p<0.001) and hypertension (adj. OR 2.893, 95% CI 1.667—5.019, p<0.001) were independent predictors of mortality in ICU patients with COVID-19. Conclusion. Coronary artery disease and hypertension are independent predictors of poor outcomes. Long-term use of angioten-sin-converting enzyme inhibitors, β-blockers, acetylsalicylic acid or statins for cardiovascular diseases does not significantly affect clinical outcomes in ICU patients with COVID-19. © 2022, Media Sphera Publishing Group. All rights reserved.